Skip to main content

Table 4 Univariate and multivariate competing risk regression analyses for distant intracranial failure (n = 156)

From: Feasibility of linac-based fractionated stereotactic radiotherapy and stereotactic radiosurgery for patients with up to ten brain metastases

 

Univariate analysis

Multivariate analysis

 

HR (95% CI)

p Value

HR (95% CI)

p Value

Number of BMs

A (1)

0.61 (0.34–1.08)

0.088

0.57 (0.31–1.02)

0.057

B (2–4)

Ref

–

Ref

–

C (5–10)

1.15 (0.58–2.26)

0.690

1.18 (0.53–2.60)

0.690

Age (years)

 < 65

Ref

–

Ref

–

 ≥ 65

1.21 (0.80–1.81)

0.368

0.49 (0.27–0.90)

0.020

Gender

Female

Ref

 

Ref

–

Male

0.78 (0.47–1.30)

0.340

0.62 (0.34–1.13)

0.120

Primary site

Lung

1.50 (0.37–6.12)

0.570

2.67 (0.63–11.41)

0.180

GI

1.75 (0.36–8.38)

0.490

3.41 (0.67–17.45)

0.140

Breast

Ref

–

Ref

–

Others

1.66 (0.38–7.34)

0.500

2.82 (0.63–12.67)

0.180

KPS

 ≥ 80

Ref

–

Ref

–

 ≤ 70

1.00 (0.59–1.69)

0.990

1.08 (0.60–1.94)

0.800

Extracranial lesions

Controlled

Ref

–

Ref

–

Uncontrolled

1.80 (0.99–3.27)

0.052

1.70 (0.94–3.09)

0.082

fSRT or SRS

SRS

Ref

–

Ref

–

fSRT

0.82 (0.48–1.37)

0.440

1.04 (0.52–2.07)

0.920

Total PTV volume (cm3)

1 (≥ 15)

0.83 (0.43–1.60)

0.580

0.70 (0.30–1.62)

0.410

2 (≥ 4, < 15)

0.64 (0.35–1.16)

0.140

0.59 (0.30–1.16)

0.130

3 (< 4)

Ref

–

Ref

–

  1. BMs Brain metastases, GI Gastrointestinal cancers, KPS Karnofsky performance status, fSRT Fractionated stereotactic radiotherapy, SRS Stereotactic radiosurgery, PTV Planning target volume
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us